Sunday 18 October 2026
Export NRXP’s income statement to Excel — free account
NRx Pharmaceuticals, Inc.
NRXP Healthcare Biotechnology
NRx Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million. In the quarter to June 2026, EPS grew 55.1% and free cash flow fell 142.6%, each against the same quarter a year earlier.
2.60
0.11
−4.06%
Follow NRXP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | 95.82 | 96.80 | 101.60 | 98.00 | 40.70 | 4.90 | 2.21 | 1.10 | 1.58 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | 109.30 | 102.55 | 120.40 | 769.90 | 642.00 | 51.50 | 14.10 | 7.33 | 6.01 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 2 | 2 | — | — | — | — | 29 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | — | — | — | — | 0.04 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 1 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | 58.78 | |||||
| EBT | — | 0 | 0 | 0 | (52) | (93) | (40) | (30) | (25) | (29) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2,336.49) | |||||
| Net income | — | 0 | 0 | 0 | (52) | (93) | (40) | (30) | (25) | (29) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | ||||
| Earnings | — | (0.01) | 0.25 | 1.47 | (15.11) | (74.40) | (6.10) | (4.00) | (2.36) | (1.34) | |||||
| Cash flow | — | (0.01) | (1.81) | (2.85) | (0.66) | (8.04) | (6.04) | (2.86) | (1.00) | (0.66) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.01) | (1.81) | (2.85) | (0.66) | (8.04) | (6.05) | (2.86) | (1.00) | (0.66) | |||||
| Book value | — | 0.55 | 19.12 | 17.97 | (12.77) | 4.43 | 1.13 | (1.55) | (2.18) | (0.74) | |||||
| Shares, m | — | 9 | 0 | 0 | 3 | 5 | 7 | 8 | 11 | 21 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (4.62) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | 0 | (1) | (2) | (38) | (40) | (22) | (11) | (14) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | — | 0 | 0 | (1) | (2) | (38) | (40) | (22) | (11) | (14) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | (1) | (1) | (43) | 21 | 10 | (12) | (19) | (20) | ||||
| Total debt | — | — | 1 | 2 | 1 | 1 | 11 | — | 7 | — | |||||
| Net debt | — | 0 | 1 | 2 | (1) | (27) | (10) | (5) | 5 | (8) | |||||
| Shareholders’ equity | — | 5 | 5 | 5 | (44) | 21 | 7 | (12) | (23) | (16) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (0.15) | 0.09 | 0.79 | (295.74) | (1,956.18) | (135.81) | (182.06) | (458.25) | (344.70) | ||||
| ROIC | — | 0.00 | (11.08) | (6.41) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | (0.15) | 1.32 | 8.17 | 267.09 | 3,038.41 | (281.79) | 1,393.99 | 143.75 | 146.18 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
NRx Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | $121.7M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $120.8M | — (loss-making) | — | — | n/m | +43.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $119.2M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $117.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | |
| HURA TuHURA Biosciences, Inc. | $116.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NERV Minerva Neurosciences, Inc | $115.6M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $114.9M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| ENGN enGene Therapeutics Inc | $114.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| SEER Seer, Inc. | $113.0M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| Median of peers | $116.1M | — | — | −49.65% | — | −44.22% | 0.00% | 0.00% |
NRx Pharmaceuticals, Inc. (NRXP) key facts
- NRx Pharmaceuticals, Inc. (NRXP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- NRx Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million.
- As of October 16, 2026, NRXP traded at $2.60, a market capitalization of $117.3 million.
- Return on equity was 146.2% and debt-to-equity -2.42.
- Its Altman Z-score is −37.82 (distress zone) for fiscal 2025.